First five patients vaccinated with the RUTI® therapeutic vaccine

The first five patients included in the study titled "Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB) after successful intensive-phase treatment" have been successfully vaccinated with the RUTI therapeutic vaccine.

The study is conducted in Eastern Europe and will evaluate the safety and immunological response of MDR-TB patients comparing the RUTI vaccinated ones versus placebo at different time points. It is expected to have results by the end of this year.

Drug-resistant TB continues to be a public health threat: in 2018, there were about half a million new cases of rifampicin-resistant TB, of which 78% had multidrug-resistant TB.